<div class="headers"><div>Table 3. Summary of AE and SAE incidence rates in Asian AS patients in the MEASURE 1 and MEASURE 2 trials†Includes patients originally randomized to placebo who were switched to secukinumab per the study designs. ‡AEs that occurred in at least 2.0% of the patients in the Any secukinumab group during the 16‐week placebo‐controlled period and events with an EAIR of at least 5.0 cases per 100 patient‐years in the Any secukinumab group during the entire treatment period. Events listed according to preferred term in the Medical Dictionary for Regulatory Activities (MedDRA version 17.0), sorted in descending order of EAIR in the Any secukinumab group for the entire treatment period. The entire treatment period for safety data was from baseline to Week 52 visit of the last patient enrolled in these studies. AE, adverse event; AS, ankylosing spondylitis; EAIR, Exposure adjusted incidence rates; N, number of randomized patients; SAE, serious adverse event; URTI, upper respiratory tract infection.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Criterion</p></td>
<td style='border-top: 2px solid grey; text-align: left;'><p style="padding-left:20px; " class="indent1 ">Placebo‐controlled period</p></td>
<td style='border-top: 2px solid grey; text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Any secukinumab (N = 49)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">Placebo (N = 23)</p></td>
</tr>
<tr>
<td style='text-align: left;'></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">No. of patients with events (%)</p></td>
<td style='text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Any AE</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">38 (77.6)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">18 (78.3)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Any SAE</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1 (2.0)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1 (4.3)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Infections and infestations</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">13 (26.5)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">3 (13.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Most common AEs‡</p></td>
<td style='text-align: left;'></td>
<td style='text-align: left;'></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Dyslipidemia</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">12 (24.5)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">3 (13.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">URTI</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1 (2.0)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1 (4.3)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Mouth ulceration</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">7 (14.3)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">3 (13.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Leukopenia</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">7 (14.3)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">0 (0.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Pharyngitis</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">2 (4.1)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">0 (0.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Nasopharyngitis</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">4 (8.2)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1 (4.3)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Osteoprotegerin decreased</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1 (2.0)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1 (4.3)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Oropharyngeal pain</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">2 (4.1)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">3 (13.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Headache</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">2 (4.1)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">3 (13.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Lymphadenopathy</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">2 (4.1)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">0 (0.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Rhinitis</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1 (2.0)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">0 (0.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Neutropenia</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1 (2.0)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">0 (0.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Gastroenteritis</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1 (2.0)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">0 (0.0)</p></td>
</tr>
<tr>
<td style='text-align: left;'><p style="" class="">Cough</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">1 (2.0)</p></td>
<td style='text-align: left;'><p style="padding-left:20px; " class="indent1 ">0 (0.0)</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="font-weight: bold; padding-left:20px; " class="indent1 bold ">†Includes patients originally randomized to placebo who were switched to secukinumab per the study designs. ‡AEs that occurred in at least 2.0% of the patients in the Any secukinumab group during the 16‐week placebo‐controlled period and events with an EAIR of at least 5.0 cases per 100 patient‐years in the Any secukinumab group during the entire treatment period. Events listed according to preferred term in the Medical Dictionary for Regulatory Activities (MedDRA version 17.0), sorted in descending order of EAIR in the Any secukinumab group for the entire treatment period. The entire treatment period for safety data was from baseline to Week 52 visit of the last patient enrolled in these studies. AE, adverse event; AS, ankylosing spondylitis; EAIR, Exposure adjusted incidence rates; N, number of randomized patients; SAE, serious adverse event; URTI, upper respiratory tract infection.</p></td>
<td style='border-bottom: 2px solid grey; text-align: left;'></td>
<td style='border-bottom: 2px solid grey; text-align: left;'></td>
</tr>
</tbody>
</table>
